Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Treadmill exercise modulates nigral and hippocampal cannabinoid receptor type 1 in the 6-OHDA model of Parkinson’s disease

Lookup NU author(s): Professor David BrooksORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Physical exercise benefits Parkinson’s disease (PD) patients but the mechanism is unclear. Cannabinoid receptor type 1 (CB1R) is known to be reduced in PD patients and animal models. We test the hypothesis that binding of the CB1R inverse agonist, [3H]SR141716A, is normalized by treadmill exercise in the toxin-induced 6-hydroxdopamine (6-OHDA) model of PD. Male rats had unilateral striatal injections of 6-OHDA or saline. After 15 days, half were submitted to exercise and half remained sedentary. [3H]SR141716A autoradiography was performed in postmortem tissue from striatum, substantia nigra (SN) and hippocampus. There was a 41% decrease of [3H]SR141716A specific binding in the ipsilateral SN of 6-OHDA-injected sedentary animals which was attenuated to 15% by exercise, when compared to saline-injected animals. No striatal differences were observed. A 30% bilateral hippocampal increase was observed in both healthy and 6-OHDA exercised groups. In addition, a positive correlation between nigral [3H]SR141716A binding and nociceptive threshold was observed in PD-exercised animals (p=0.0008), suggesting a beneficial effect of exercise in the pain associated with the model. Chronic exercise can reduce the detrimental effects of PD on nigral [3H]SR141716A binding, similar to the reported reduction after dopamine replacement therapy, so should be considered as an adjunct therapy for PD.


Publication metadata

Author(s): Binda KH, Landau AM, Chacur M, Brooks DJ, Real CC

Publication type: Article

Publication status: Published

Journal: Brain Research

Year: 2023

Volume: 1814

Print publication date: 01/09/2023

Online publication date: 01/06/2023

Acceptance date: 29/05/2023

Date deposited: 12/06/2023

ISSN (print): 0006-8993

ISSN (electronic): 1872-6240

Publisher: Elsevier BV

URL: https://doi.org/10.1016/j.brainres.2023.148436

DOI: 10.1016/j.brainres.2023.148436


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
17/05218-5
17/26821-1
18/25204-1
The Sao Paulo Research Foundation

Share